You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said it has developed a POC test that uses a biomarker for HPV16, which is responsible for more than 90 percent of all HPV-related head and neck tumors.
The company plans to publish new data on clinical sensitivity and specificity and has initiated multiple studies investigating new use cases.
The German biotech firm said its lateral flow blood test does not detect subclinical HPV infection but picks up on HPV-induced cancers and pre-cancers.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
The partners will integrate CCPM's research biobank with personalized genomic information to develop and commercialize the saliva-based tests.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
The system showed good performance for cervical samples as well as orophyrengeal samples, and required no extraction step.
Clinicians can use the PD-L1 IHC 22C3 pharmDx assay to help identify head and neck squamous cell carcinoma patients for treatment with Merck's Keytruda in Europe.
Cyclomics, a 2018 spinout from University Medical Center Utrecht, is testing its assay for treatment response and recurrence monitoring in head and neck cancer.
The diagnostic can now be used to identify patients with head and neck squamous cell carcinoma who may benefit from first-line treatment with Keytruda.